Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pliant Therapeutics ( (PLRX) ) just unveiled an announcement.
Pliant Therapeutics announced that on April 14 and April 16, 2026, directors David E.I. Pyott and Katharine Knobil, M.D., notified the company of their plans to retire from its board and committees effective at the 2026 Annual Meeting of Stockholders. On April 16, 2026, director Suzanne Bruhn, Ph.D., likewise informed the company she would not stand for reelection and would retire at the meeting, with all three departures stated as unrelated to any disagreements over operations or governance.
The board also approved on April 15, 2026, an option repricing effective April 17, 2026, resetting underwater employee stock options granted on or before March 1, 2025 to an exercise price of $1.33 per share, contingent on specified retention periods and conditions. Designed to retain and motivate employees and executives without additional equity dilution or cash costs, the move seeks to align incentives at a critical stage for the company after a broad decline left all outstanding employee options out of the money.
The most recent analyst rating on (PLRX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Pliant Therapeutics stock, see the PLRX Stock Forecast page.
Spark’s Take on PLRX Stock
According to Spark, TipRanks’ AI Analyst, PLRX is a Neutral.
The score is primarily held back by weak financial performance—ongoing losses, consistent negative free cash flow, and a shrinking equity cushion. Technicals provide some support via improving short-term momentum, but longer-term trend signals remain soft, and valuation is constrained by negative earnings and no stated dividend yield.
To see Spark’s full report on PLRX stock, click here.
More about Pliant Therapeutics
Pliant Therapeutics, Inc. is a biotechnology company focused on developing novel therapies, including small-molecule and biologic candidates, targeting fibrotic and related diseases. The company operates in the biopharmaceutical industry, with its stock listed on The Nasdaq Global Select Market, and emphasizes research and development-driven growth for its shareholders.
Average Trading Volume: 663,222
Technical Sentiment Signal: Sell
Current Market Cap: $81.11M
Learn more about PLRX stock on TipRanks’ Stock Analysis page.